Google Alert - "Myeloproliferative neoplasms" OR "polycythemia vera" OR myelofibrosis OR "essential thrombocythemia" · Scour

Selinexor plus ruxolitinib nearly doubled spleen response and improved survival in myelofibrosis

Patients With MPN Have Greater Risk of Developing Second Malignancies

Karyopharm Shares Jump 10% Following Mixed Phase 3 Trial Outcomes on Myelofibrosis Treatment

Why Did KPTI Stock Tank 13% In Pre-Market Today?

Karyopharm's myelofibrosis trial meets one of two primary goals

Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint ...

Karyopharm's SENTRY Phase 3 Trial In Myelofib...

Karyopharm Therapeutics announces topline results from Phase 3 SENTRY trial in myelofibrosis

Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint ...

KPTI: Phase 1 Myelofibrosis Data Will Support 2026 Frontline Opportunity

JAK Inhibitors May Improve Transplantation Outcomes in Myelofibrosis

Researchers develop targeted therapy for rare blood cancer

Incyte Outlines Post-Jakafi Growth Strategy at Barclays Conference

Ryvu Therapeutics Reports 2025 Fiscal Year Financial Results and Provides Corporate Update

Subtype-Specific Patterns May Be Associated With AML and MDS Risk

Interleukin-2 and Tretinoin for Myeloproliferative Neoplasms and to Target Type 1 ...

Damora Therapeutics Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

Optimizing Future Combination Approaches in Myelofibrosis

Damora Therapeutics (NASDAQ: DMRA) pivots to mutCALR MPN antibody drugs

Blood | Vol 147, Issue 12, Pages 1239-1382 (19 March 2026)

Log in to enable infinite scrolling